ライフサイエンスコーパス: nongenomic

1 impact of smoking on these tumors is mainly nongenomic.

2 aurora kinases through both an Akt-mediated nongenomic action and a transcription-dependent genomic

3 E(2) up-regulates aromatase expression by a nongenomic action of ER alpha via cross-talk with growth

4 Our results provide evidence for an early nongenomic action of ER on SRC-3 that supports the well-

5 bed the identification of MNAR (modulator of nongenomic action of estrogen receptor) as a novel scaff

6 Cav-1 is essential for this nongenomic action of GR, as DEX effects on GJIC, Cx43 ph

7 uction, indicating that the influence of the nongenomic action of TCDD lasts a long time in this cell

8 cause for the long-lasting influence of this nongenomic action of TCDD, we tested the effects of AACO

9 election as the mechanism for inhibiting the nongenomic action of tRXRalpha and provide molecular ins

10 s a membrane-initiated, non-AR-mediated, and nongenomic action.

11 t their function in the cytoplasm to control nongenomic actions is also crucial.

12 -(OH)2D3, which specifically antagonizes the nongenomic actions of 1alpha, 25-(OH)2D3, abolished 1alp

13 , plays an important role in the genomic and nongenomic actions of ER.

14 t plays an important role in the genomic and nongenomic actions of estrogen receptor by interacting w

15 Although nongenomic actions of estrogens have been suggested by n

16 Similar mechanisms may underly the nongenomic actions of other steroid hormones.

17 However, whether the newly described nongenomic actions of STAT3 toward mitochondrial oxidati

18 tures of membrane receptors mediating rapid, nongenomic actions of steroids have not been identified.

19 Evidence for nongenomic actions of steroids is now coming from a vari

20 The molecular targets accounted for many nongenomic actions of thyroid hormones are mostly unknow

21 tors, these chemicals are suspected to exert nongenomic actions on muscle function that are not well

22 Estrogen exerts a variety of nongenomic actions, which may allow for future therapeut

23 ue to estrogen receptor (ER) alpha-mediated, nongenomic activation of endothelial NO synthase (eNOS).

24 f estrogen receptors by estradiol triggers a nongenomic activation of PI3 kinase that results in enha

25 ggest that mitochondria are novel players in nongenomic activities of AR.

26 Additionally, nonnuclear or nongenomic activities of the AR have long been described

27 molecules and suggest that ER "genomic" and "nongenomic" activities are interrelated.

28 ntify a signaling pathway initiated from the nongenomic activity of all-trans retinoic acid (atRA) to

29 protein 1 (PELP1), also called modulator of nongenomic activity of estrogen receptor (MNAR), a novel

30 leucine-rich protein 1 (PELP1)/modulator of nongenomic activity of estrogen receptor (MNAR), a novel

31 teracting protein designated as modulator of nongenomic activity of estrogen receptor (MNAR).

32 h protein-1) (also known as the modulator of nongenomic activity of estrogen receptor) plays a role i

33 1 (also referred to as MNAR, or modulator of nongenomic activity of estrogen receptor)), a recently i

34 1,25(OH)(2)D(3) and the nongenomic agonist 1alpha,25-dihydroxylumisterol(3) redu

35 HIPs contain nongenomic amino acid sequences and have been identified

36 lation of P450C24 by 1,25VD has both a rapid nongenomic and a slower genomic component that are funct

37 TCR-induced T cell proliferation are mainly nongenomic and can be bypassed by the activation of an L

38 ly to exert a long-lasting analgesia through nongenomic and possibly genomic effects.

39 with evidence at the molecular level of fast/nongenomic and slow/genomic or conversion-based mechanis

40 anisms regulating transcription-independent (nongenomic) androgen actions are poorly understood.

41 l complexity and highlight novel genomic and nongenomic approaches that offer insight into the underl

42 thelial cells, IAA activated an inflammatory nongenomic aryl hydrocarbon receptor (AhR)/p38MAPK/NF-ka

43 SHRs also mediate rapid, nongenomic cellular activation by steroids.

44 Ts acetylate nonhistone proteins involved in nongenomic cellular processes, such as estrogen receptor

45 t of estrogen on the vessel wall has a rapid nongenomic component involving membrane phenomena, such

46 effects of cortisol, we addressed the rapid, nongenomic cortisol effects on in vivo neuronal activity

47 TA may decrease VEGF synthesis by nongenomic destabilization of VEGF mRNA in cobalt-stimul

48 ded DNA viruses that can package and deliver nongenomic DNA for therapeutic gene delivery.

49 ssion was restored within 15 min, suggesting nongenomic E2 effects at membrane estrogen receptors.

50 Despite involving the ER, this is a nongenomic effect E2, as demonstrated by maintained resp

51 not inhibited by actinomycin D, suggesting a nongenomic effect of aldosterone.

52 t of these changes, which are initiated by a nongenomic effect of glucocorticoid receptors, were also

53 rapidly activate PI 3-K/Akt in these cells (nongenomic effect).

54 ns of these secosteroids involve both rapid, nongenomic effects and genomic effects; the latter media

55 Bile acids exert genomic and nongenomic effects by interacting with membrane G-protei

56 Cortisol via these receptors induces rapid nongenomic effects followed by slower genomic effects, w

57 Thyroid hormones induce short-latency nongenomic effects in adult brain tissue, suggesting tha

58 In cooperation with genomic actions, nongenomic effects may play a role in feedback regulatio

59 Although nongenomic effects of 17beta-estradiol (E2) are mediated

60 They furthermore argue that nongenomic effects of aldosterone play no significant ro

61 Here we examine the nongenomic effects of dihydrotestosterone (DHT) in prost

62 Overall, these results elucidate additional nongenomic effects of DM and the GCR on resting human T

63 lowing trauma-hemorrhage, we examined if the nongenomic effects of estradiol on cardiac function afte

64 eptor 30 (GPR30) is a receptor implicated in nongenomic effects of estradiol, and the aim of this stu

65 We examined rapid, nongenomic effects of estradiol.

66 eceptor (GPER) mediates both the genomic and nongenomic effects of estrogen and has been implicated i

67 Functional nongenomic effects of nuclear receptors are poorly under

68 Among the nongenomic effects of steroids, control of vasomotion ha

69 Steroid hormones have rapid nongenomic effects on cell-signaling pathways, but the r

70 to have both genomic, i.e., through TRs, and nongenomic effects on cells.

71 Given that ERs have rapid, nongenomic effects on HPC-dependent STM, we investigated

72 to the salt status induces both genomic and nongenomic effects that by promoting endothelial dysfunc

73 Genomic and nongenomic effects were thought to be disparate and inde

74 ty is critically involved in mediating these nongenomic effects, because its inhibition prevents both

75 E receptors (ER); and (ii) relatively rapid nongenomic effects, such as kinase activation and calciu

76 hat in these contexts the JNK pathway exerts nongenomic effects.

77 ifferentiation, and survival via genomic and nongenomic effects.

78 ent studies suggest the importance of acute, nongenomic effects.

79 The effect is mediated by FXR by nongenomic elements, suggesting a novel link between FXR

80 lso influences STM in the dHPC, possibly via nongenomic ER activity.

81 ion and some of the early G1 genes through a nongenomic, ER-independent signaling pathway.

82 Tamoxifen, a nongenomic ERbeta agonist, down-regulates Sost expressio

83 r the classic ERE pathway support a role for nongenomic ERbeta in the development of smoking-associat

84 to bind 17B-estradiol (E2) and mediate rapid nongenomic estrogen responses, hence also named G protei

85 -alpha36, and found that ER-alpha36 mediated nongenomic estrogen signaling and is highly expressed in

86 cycling females, and to identify a role for nongenomic estrogen signaling in any form of respiratory

87 , thus demonstrated that ER-alpha36 mediates nongenomic estrogen signaling through the EGFR/Src/ERK s

88 The ability of nongenomic estrogen signaling within the cervical spinal

89 rc and ERalpha/PI3K expression, hallmarks of nongenomic estrogen signaling, reinforcing the link betw

90 omplex, central to the rapid transduction of nongenomic estrogen signals.

91 as a molecular scaffold required for rapid, nongenomic estrogen-mediated activation of downstream si

92 of cells fated to become resistant through a nongenomic estrogen-mediated mechanism.

93 We have elucidated a nongenomic extranuclear signal mediated by the RAR-SRC i

94 Among the nongenomic factors, age and body mass index contributed

95 stimulation, which supports the notion that nongenomic function of androgen is mediated by its inter

96 Our results suggest that enhanced nongenomic function of ERalpha via cooperation with the

97 Our results reveal acute and rapid nongenomic functions for estradiol in central auditory p

98 tial for the modulation of transcription and nongenomic functions in many target cells.

99 alpha and ERbeta), modulates the genomic and nongenomic functions of the ERs.

100 and indicate that PELP1-mediated genomic and nongenomic functions play a role in the growth factor-me

101 gen receptor via histone interactions and in nongenomic functions via its influence on the MAPK-Src p

102 rogen receptor and modulates its genomic and nongenomic functions.

103 We demonstrate a nongenomic glucocorticoid induction of long-lasting supp

104 nd pulse is precisely timed and depends on a nongenomic glucocorticoid receptor-dependent pathway.

105 ession but not enhanced cell-cycle exit, the nongenomic GR signaling pathway may operate via distinct

106 echanism employed by mSlo1, hSlo1 exhibits a nongenomic hERalpha-mediated regulatory mechanism.

107 ed to the coevolution between host and other nongenomic, horizontally transferred pathogens.

108 This nongenomic influence of the GR contributes to activation

109 trate that brain-generated E2 engages, via a nongenomic interaction between an estrogen receptor and

110 mediated by ERalpha functioning in a novel, nongenomic manner to activate eNOS via MAP kinase-depend

111 te some of the effects of PPAR agonists in a nongenomic manner.

112 se responses are consistent, in part, with a nongenomic mechanism and are steroid specific at the rec

113 Together, these data demonstrate a new nongenomic mechanism by which E(2) prevents apoptosis.

114 alpha-DHP by a genomic action, and ALLO by a nongenomic mechanism down-regulate the action of drugs a

115 in promoting tumor progression, unveiling a nongenomic mechanism for EGFR overproduction in human br

116 oid receptor from its K+ channel, implying a nongenomic mechanism of action by E2.

117 butes to alcohol behavioral sensitivity by a nongenomic mechanism that diverges from the NF-kappaB tr

118 cription factor, is also involved, through a nongenomic mechanism, in the regulation of both intracel

119 ated glucose-induced insulin secretion via a nongenomic mechanism.

120 sion of the human brain in vivo via a rapid, nongenomic mechanism.

121 to airway mucosal vasoconstriction through a nongenomic mechanism.

122 he strength of inhibitory transmission via a nongenomic mechanism.

123 synthesis within 5 min, supporting a rapid, nongenomic mechanism.

124 s often associated with specific genomic and nongenomic mechanisms of immune escape.

125 highlight recent studies that elucidate the nongenomic mechanisms of PPAR ligand-induced MAPK phosph

126 The results suggest that both genomic and nongenomic mechanisms of these compounds are involved wi

127 The nongenomic mechanisms underlying transitions and interac

128 ids exert complex regulation via genomic and nongenomic mechanisms, acting mainly by downregulating p

129 Rald effectively induced Atgl levels via nongenomic mechanisms, demonstrating indirect regulation

130 ippocampal synaptic plasticity through rapid nongenomic mechanisms, possibly by binding to plasma mem

131 may exert some of its effects through rapid nongenomic mechanisms, possibly by binding to plasma mem

132 enerate biological responses via genomic and nongenomic mechanisms.

133 ainst kidney injury through both genomic and nongenomic mechanisms.

134 he cytoskeleton to epigenetic regulation and nongenomic mechanisms.

135 te these cells' cytoskeletal architecture by nongenomic mechanisms.

136 t likely mediated in part by activation of a nongenomic, membrane-associated, signaling pathway invol

137 ough membrane P4 receptors (mPRs) in a rapid nongenomic modality.

138 Furthermore, our results demonstrate a novel nongenomic mode for nuclear receptor action and a functi

139 Nongenomic modulation of BK activity by steroids is incr

140 Here, we reveal the nongenomic molecular mechanism of progesterone as the ac

141 ic mineralocorticoid receptor (MR)-mediated, nongenomic MR-dependent, and nongenomic non-MR dependent

142 ocking, at least partially, both genomic and nongenomic MR-mediated effects.

143 ivates vascular inflammation in part through nongenomic, MR-mediated pathways.

144 caveolae and are required for initiation of nongenomic (NG) responses.

145 (MR)-mediated, nongenomic MR-dependent, and nongenomic non-MR dependent actions.

146 hosphorylation cascades, referred to as the "nongenomic," or extranuclear, action.

147 a well-established physiological readout of nongenomic P4 signaling, we demonstrate that mPRbeta sig

148 a well-established physiological readout of nongenomic P4 signaling, we identify the lipid hydrolase

149 ution than immunity genes that interact with nongenomic pathogens in Drosophila.

150 , suggesting the possible involvement of the nongenomic pathway of action of TCDD as shown previously

151 This nongenomic pathway operates through lipid raft-associate

152 ptional (genomic pathway) and translational (nongenomic pathway) level.

153 ses is carried out through a characteristic "nongenomic" pathway, which is clearly different from the

154 Since studies suggest that both genomic and nongenomic pathways are involved in mediating the saluta

155 Androgens also act through nongenomic pathways in certain cell types to evoke rapid

156 These data show that T can act through fast nongenomic pathways in the liver.

157 mone receptors and the effect of genomic and nongenomic pathways of sex hormones following trauma.

158 estrogen signaling through both genomic and nongenomic pathways, as well as the mechanisms by which

159 y believed and demonstrates the relevance of nongenomic pathways, which have, thus far, remained unex

160 rease aggression in short days primarily via nongenomic pathways.

161 and neuroprotective effects via genomic and nongenomic pathways.

162 diated through induction of both genomic and nongenomic pathways.

163 h a target gene, but it can also act through nongenomic pathways.

164 These results indicate that the nongenomic PI3K signaling pathway plays a role in estrog

165 rtant role of CatSper channel in human sperm nongenomic progesterone signaling and demonstrate that t

166 the density and distribution of genomic and nongenomic receptors that serve as transcriptional regul

167 n central GRs and NMDARs through genomic and nongenomic regulation may be an important mechanism crit

168 membrane form of ERalpha involved in rapid, nongenomic responses to estrogens.

169 ionally with E2-stimulated genomic and rapid nongenomic responses, respectively.

170 rol, which is a potent agonist of the rapid, nongenomic responses, was equipotent with 1alpha, 25-(OH

171 genomes in the context of a large excess of nongenomic RNA.

172 eptor-mediated mechanism, and they suggest a nongenomic role for estrogen in the modulation of NO-dep

173 athway is active in platelets and implying a nongenomic role for IKK.

174 The relative importance of this nongenomic role for the glucocorticoid receptor compared

175 d-receptor or separately, play extranuclear, nongenomic roles that greatly expand the multiple mechan

176 These results suggest that the nongenomic salutary effect of E2 in reducing hepatic inj

177 thway plays a critical role in mediating the nongenomic salutary effects of estradiol on cardiac func

178 providing a mechanism for the acquisition of nongenomic sequences.

179 We compared their nongenomic signaling and functional actions in GH3/B6/F1

180 To investigate the role of G proteins in nongenomic signaling by progesterone, the effects of mod

181 f Xenopus oocytes is a well known example of nongenomic signaling by steroids; however, little is kno

182 y a crucial role in modulating the status of nongenomic signaling by using molecular mechanisms that

183 gical concentration of atRA triggers a rapid nongenomic signaling cascade to suppress Oct4 gene and r

184 easing evidence that GCs also initiate rapid nongenomic signaling events in a variety of cell types.

185 ogen receptors, it also initiates many rapid nongenomic signaling events.

186 receptor is involved in progesterone-induced nongenomic signaling in Xenopus oocytes and provide evid

187 Thus, this study demonstrates a rapid, nongenomic signaling mechanism for ovarian-derived estro

188 To test tissue specificity of this nongenomic signaling mechanism, we tested retinal and br

189 rogen receptor-alpha (ER-alpha) can initiate nongenomic signaling mechanisms that modulate synaptic p

190 ctivation of S1P receptors may contribute to nongenomic signaling of E(2) important for breast cancer

191 We conclude that androgen actively evokes a nongenomic signaling pathway to activate PKA that is nee

192 The discovery of this nongenomic signaling pathway, in which glucocorticoids a

193 genomic actions, are strong estrogens in the nongenomic signaling pathways and functional responses i

194 Three nongenomic signaling pathways were explored: Src, Rho, a

195 immediate actions on neostriatal neurons via nongenomic signaling pathways.

196 We also examined whether the nongenomic signaling properties of XPR can account for t

197 Intriguingly, E(2) nongenomic signaling, antioxidant action, and neuroprote

198 GPR30 can mediate E(2)-induced nongenomic signaling, but its role in ERalpha-positive b

199 r estrogen receptor alpha (ERalpha)-mediated nongenomic signaling, involving Akt activation and subse

200 e established physiological importance of P4 nongenomic signaling, the details of its signal transduc

201 the classical progesterone receptor in this nongenomic signaling.

202 or membrane P4 receptors (mPRs) that mediate nongenomic signaling.

203 oints, suggesting involvement of genomic and nongenomic signaling.

204 mERbeta, and GPER/GPR30), thereby initiating nongenomic signaling.

205 Sp1 or AP-1 sites, to target genes) and/or "nongenomic" (signaling) mechanisms.

206 een NO and ER may favor activation of rapid (nongenomic) signaling pathways and subsequent modulation

207 E(2) also activates nongenomic signals via an extranuclear form of ERalpha a

208 The MBSP may mediate rapid nongenomic steroid effects that contribute to steroid-in

209 -protein activity, suggesting a postsynaptic nongenomic steroid signaling mechanism that stimulates t

210 diated oocyte maturation as well as in other nongenomic steroid-induced signaling events.

211 blockers suggest that mitochondria are early nongenomic targets of E2.

212 Our experimental data reveal novel nongenomic targets of pregnenolone and provide important

213 remainder involves unrepaired DNA lesions or nongenomic targets.

214 r, high intermodel variability and permanent nongenomic transcriptional changes constrain their use f

215 that ERalpha may serve as both a genomic and nongenomic transducer of estrogen action in the HF.

216 suggest that ERbeta may serve primarily as a nongenomic transducer of estrogen actions in the hippoca

217 he role of arginine vasopressin (AVP) in the nongenomic transfer of paternal behavior from fathers to

218 r smooth muscle cells may explain the acute, nongenomic vasodilator actions of environmental estrogen

219 Therefore, nongenomic viral transcripts, short replication intermed

220 , by demonstrating independent regulation of nongenomic vs. genomic ER-dependent signaling, these fin